Tafolecimab and sintilimab plus chemo for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a new combination of treatments, including an immune drug (sintilimab) and a cholesterol-lowering drug (tafolecimab), along with chemotherapy, for people with advanced lung cancer that no longer responds to standard immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage IIIB–IV) non-small cell lung cancer that has gotten worse after first-line treatment with an immunotherapy drug like Keytruda or Opdivo.
- Your tumor does not have an EGFR or ALK gene mutation (these are usually treated with other drugs).
- You are between 18 and 75 years old, and your general health is good (ECOG score 0 or 1 – meaning you are quite active).
- You must have at least one tumor that can be measured on a CT or MRI scan.
- If the cancer has spread to your brain, it must be stable (not causing new problems) and controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a combination of the immunotherapy drug tislelizumab, standard chemotherapy, and an antihistamine (diphenhydramine) as a first treatment for advanced non-small cell lung cancer. The antihistamine may help reduce side effects or improve the immune response.
This trial tests a combination of two drugs—golidocitinib (a targeted pill) and sintilimab (an immunotherapy)—for people with advanced non-small cell lung cancer that has a high PD-L1 protein level. It may offer a new option if you haven't had immunotherapy before.
This trial tests whether adding a cholesterol-lowering drug to a combination of two other drugs can help people with advanced non-small cell lung cancer whose cancer has grown after prior immunotherapy. It aims to find a new treatment option for those who have run out of standard options.
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy to shrink inoperable stage IIIC lung cancer. The goal is to make the cancer small enough to remove with surgery and improve survival.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.